ImmunoMet appoints two new executives

ImmunoMet Therapeutics, a private US-based biotechnology company, on Monday appointed two new executives, for medical and financial departments.

The company focused on utilizing cellular metabolism to develop novel anti-tumor and immuno-oncology therapies said that Vincent J. O’Neill, will be the new Chief Medical Officer and Allan J. Shaw is taking the responsibility of a Chief Financial Officer.

Benjamin Cowen, Chief Executive Officer of ImmunoMet, said that the addition of the industry veterans, with experience from the major drugmakers such are Roche, GSK which, will strengthen ImmunoMet’s management team. “We are enthusiastic about the extensive experience and leadership that Vince and Allan bring to the company. Their expertise will prove invaluable as we continue to advance our lead clinical program, IM156, an OXPHOS inhibitor, designed to treat drug resistant cancers and, also, as we further advance ImmunoMet’s biguanide platform bringing innovative therapies to patients,” said Cowen.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.